To compare & evaluate the efficacy of artificial bone particles with specialized blood clot in the treatment of severe gum disease

Comparative Clinical & Radiographic Evaluation of Autologous Advanced Platelet Rich Fibrin (A-PRF+) with Bioactive Glass (PerioGlas®) & Autologous Advanced Platelet Rich Fibrin (A-PRF+) with Demineralized Freeze Dried Bone Allograft (DFDBA) in the Treatment of Intrabony Defects in Chronic Periodontitis Patients- A Randomized Clinical Trial

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/11/059644

Enrollment

Registered

2023-11-07

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: M278- Other specified diseases of jaws Health Condition 3: M858- Other specified disorders of bonedensity and structure

Interventions

Intervention1: Autologous Advanced Platelet Rich Fibrin (A-PRF) with Bioactive Glass: Autologous Advanced Platelet Rich Fibrin (A-PRF) with Bioactive Glass (PerioGlas®) duration- 1 day Control Interve

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients in the age group between 30-60 yrs. 2)Patients diagnosed with Chronic Periodontitis. 3)Patients who are non-smokers or do not consume tobacco in any other form. 4)Patients are in good systemic health with no contraindication to periodontal surgery. 5) Patients having pocket depths >5mm, intraosseous defects > 3mm and with radiographic evidence of vertical / angular bone loss in the affected sites.

Exclusion criteria

Exclusion criteria: 1) One-walled osseous defects. 2) Patients suffering from any systemic diseases or with a compromised immune system. 3) Patients who had received any type of periodontal therapy for the past 6 months. 4) Patients taking immunosuppressant drugs like corticosteroids. 5) Patients with a known history of allergy to Doxycycline or Chlorhexidine or any other medicine used in the study. 6) Patients showing unacceptable oral hygiene compliance during / after Phase I periodontal therapy. 7) Patients taking any drug known to cause gingival enlargement. 8) Pregnant and/or lactating mothers.

Design outcomes

Primary

Measure	Time frame
1.Plaque Index (P.I.) (Tureskey-Gilmore-Glickman Modification of Quigley Hein) 2.Gingival Index (G.I.) (Loe & Silness, 1963) 3.Probing Pocket Depth (PPD) 4.Clinical Attachment Level (CAL) Timepoint: Baseline, 1 Month, 3 Months, 6 Months	—

Secondary

Measure	Time frame
Measurement of bone fill from CEJ to the base of the defect using radiovisiography (RVG) with EzDenti imaging softwareTimepoint: Baseline, 1 Month, 3 Months, 6 Months	—

Countries

India

Contacts

Public ContactDr Monika Patil

Nair Hospital Dental College

maladixit25@gmail.com9223340938

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026